Literature DB >> 12410796

Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4.

T Christophe1, A Karlsson, M-J Rabiet, F Boulay, C Dahlgren.   

Abstract

Lipoxin A4 (LXA4) has been shown to bind to the leucocyte formyl peptide receptor (FPR) homologue, FPRL1, without triggering the biological activities induced by other FPRL1 agonists. We investigated the direct effect of LXA4 as well as the effect on agonist-induced biological responses using transfected HL-60 cells expressing FPR, FPRL1 or FPRL2. LXA4 neither induced an intracellular rise in calcium in these transfectants nor affected the response induced by the peptide Trp-Lys-Tyr-Met-Val-Met (WKYMVM), an agonist that activates cells through FPRL1 and -2. Both agonists induced Erk-2 activation; however, the eicosanoid-induced activity was independent of FPRL1 and FPRL2. Moreover, LXA4 was unable to trigger neutrophil upregulation of complement receptor 3 and respiratory burst, and it had no effect on the responses induced by triggering with WKYMVM. We conclude that LXA4 is unable to affect the WKYMVM-induced signalling through FPRL1 and suggest that it acts through a receptor different from FPRL1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410796     DOI: 10.1046/j.1365-3083.2002.01149.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  16 in total

1.  Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Liliya N Kirpotina; Lars Brive; Claes Dahlgren; Mark A Jutila; Mark T Quinn
Journal:  J Mol Model       Date:  2011-11-30       Impact factor: 1.810

2.  Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.

Authors:  Agostino Cilibrizzi; Igor A Schepetkin; Gianluca Bartolucci; Letizia Crocetti; Vittorio Dal Piaz; Maria Paola Giovannoni; Alessia Graziano; Liliya N Kirpotina; Mark T Quinn; Claudia Vergelli
Journal:  Bioorg Med Chem       Date:  2012-04-27       Impact factor: 3.641

3.  Synthesis, HPLC enantioresolution, and X-ray analysis of a new series of C5-methyl pyridazines as N-formyl peptide receptor (FPR) agonists.

Authors:  Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Alessia Graziano; Claudia Vergelli; Gianluca Bartolucci; Giacomo Soldani; Mark T Quinn; Igor A Schepetkin; Cristina Faggi
Journal:  Chirality       Date:  2013-06-06       Impact factor: 2.437

4.  Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.

Authors:  Enza Lacivita; Igor A Schepetkin; Madia L Stama; Liliya N Kirpotina; Nicola A Colabufo; Roberto Perrone; Andrei I Khlebnikov; Mark T Quinn; Marcello Leopoldo
Journal:  Bioorg Med Chem       Date:  2014-12-13       Impact factor: 3.641

5.  Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Authors:  Liliya N Kirpotina; Andrei I Khlebnikov; Igor A Schepetkin; Richard D Ye; Marie-Josèphe Rabiet; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

6.  A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Authors:  Aram Elagoz; Duncan Henderson; Poda Suresh Babu; Sylvia Salter; Caroline Grahames; Lorna Bowers; Marie-Odile Roy; Patricia Laplante; Eric Grazzini; Sultan Ahmad; Paola M C Lembo
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

8.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

9.  6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.

Authors:  Agostino Cilibrizzi; Mark T Quinn; Liliya N Kirpotina; Igor A Schepetkin; Jeff Holderness; Richard D Ye; Marie-Josephe Rabiet; Claudio Biancalani; Nicoletta Cesari; Alessia Graziano; Claudia Vergelli; Stefano Pieretti; Vittorio Dal Piaz; Maria Paola Giovannoni
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  Tumour necrosis factor (TNF)-alpha primes murine neutrophils when triggered via formyl peptide receptor-related sequence 2, the murine orthologue of human formyl peptide receptor-like 1, through a process involving the type I TNF receptor and subcellular granule mobilization.

Authors:  Karin Onnheim; Johan Bylund; Francois Boulay; Claes Dahlgren; Huamei Forsman
Journal:  Immunology       Date:  2008-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.